Literature DB >> 34070605

Higher EU-TIRADS-Score Correlated with BRAF V600E Positivity in the Early Stage of Papillary Thyroid Carcinoma.

Karolina Skubisz1, Joanna Januszkiewicz-Caulier2, Patrycja Cybula1, Elwira Bakuła-Zalewska3, Krzysztof Goryca4, Agnieszka Paziewska1,5, Filip Ambrożkiewicz5, Kosma Woliński6, Michał Mikula5, Jerzy Ostrowski1,5, Marek Dedecjus2.   

Abstract

The data demonstrating a correlation between sonographic markers of malignancy of thyroid cancer (TC) and its genetic status are scarce. This study aimed to assess whether the addition of genetic analysis at the preoperative step of TC patients' stratification could aid their clinical management. The material consisted of formalin-fixed paraffin-embedded tumor fragments of 49 patients who underwent thyroidectomy during the early stages of papillary TC (PTC). Tumor DNA and RNA were subjected to next-generation sequencing (NGS) on Ion Proton using the Oncomine™ Comprehensive Assay panel. We observed a significant correlation between BRAF V600E and a higher EU-TIRADS score (p-value = 0.02) with a correlation between hypoechogenicity and taller-than-wide tumor shape in analysed patients. There were no other significant associations between the identified genetic variants and other clinicopathological features. For TC patient's stratification, a strong suspicion of BRAF V600E negativity in preoperative management of TC patients could limit the over-treatment of asymptomatic, very low-risk, indolent disease and leave room for active surveillance.

Entities:  

Keywords:  BRAF V600E; EU-TIRADS; histological aggressiveness; overtreatment; papillary thyroid carcinoma

Year:  2021        PMID: 34070605     DOI: 10.3390/jcm10112304

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  58 in total

1.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

Authors:  Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo
Journal:  Genome Res       Date:  2010-07-19       Impact factor: 9.043

2.  Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with "suspicious for malignant" cytology alone even when the nodules do not show suspicious US features.

Authors:  Jae Young Seo; Eun-Kyung Kim; Jin Young Kwak
Journal:  Endocrine       Date:  2014-01-23       Impact factor: 3.633

3.  Value of BRAF V600E in High-Risk Thyroid Nodules with Benign Cytology Results.

Authors:  X Chen; Q Zhou; F Wang; F Zhang; H Du; Q Zhang; W Wu; X Gong
Journal:  AJNR Am J Neuroradiol       Date:  2018-11-29       Impact factor: 3.825

4.  Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma.

Authors:  Adam S Kabaker; Mitchell E Tublin; Yuri E Nikiforov; Michaele J Armstrong; Steven P Hodak; Michael T Stang; Kelly L McCoy; Sally E Carty; Linwah Yip
Journal:  Thyroid       Date:  2012-04-23       Impact factor: 6.568

5.  Comparison of the costs of active surveillance and immediate surgery in the management of low-risk papillary microcarcinoma of the thyroid.

Authors:  Hitomi Oda; Akira Miyauchi; Yasuhiro Ito; Hisanori Sasai; Hiroo Masuoka; Tomonori Yabuta; Mitsuhiro Fukushima; Takuya Higashiyama; Minoru Kihara; Kaoru Kobayashi; Akihiro Miya
Journal:  Endocr J       Date:  2016-09-22       Impact factor: 2.349

6.  Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.

Authors:  Seo-Jin Park; Je Young Hannah Sun; Kyungran Hong; Jin Young Kwak; Eun-Kyung Kim; Woung Youn Chung; Jong Rak Choi
Journal:  Clin Chem Lab Med       Date:  2013-08       Impact factor: 3.694

7.  The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.

Authors:  Daniele Barbaro; Roberto Mario Incensati; Gabriele Materazzi; Giuseppe Boni; Mariano Grosso; Erica Panicucci; Paola Lapi; Cristina Pasquini; Paolo Miccoli
Journal:  Endocrine       Date:  2013-08-08       Impact factor: 3.633

8.  The features of contrast enhanced ultrasound and BRAF V600E in papillary thyroid carcinoma.

Authors:  Zi-Mei Lin; Cao-Xin Yan; Yue Song; Yu-Rong Hong; Qing Wen; Yong-Yuan Xu; Min-Qiang Pan; Qin Ye; Pin-Tong Huang
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

9.  Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality.

Authors:  Rengyun Liu; Justin Bishop; Guangwu Zhu; Tao Zhang; Paul W Ladenson; Mingzhao Xing
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777

Review 10.  Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome.

Authors:  Myriem Boufraqech; Naris Nilubol
Journal:  Cancers (Basel)       Date:  2019-12-10       Impact factor: 6.639

View more
  3 in total

1.  Summary of Meta-analyses of Studies Involving TIRADS Classifications (EU-TIRADS, ACR-TIRADS, and K-TIRADS) in Evaluating the Malignant Potential of Focal Lesions of The Thyroid Gland.

Authors:  Katarzyna Dobruch-Sobczak; Zbigniew Adamczewski; Marek Dedecjus; Andrzej Lewiński; Bartosz Migda; Marek Ruchała; Anna Skowrońska-Szcześniak; Ewelina Szczepanek-Parulska; Klaudia Zajkowska; Agnieszka Żyłka
Journal:  J Ultrason       Date:  2022-04-27

Review 2.  Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.

Authors:  Maciej Ratajczak; Damian Gaweł; Marlena Godlewska
Journal:  Int J Mol Sci       Date:  2021-10-31       Impact factor: 5.923

3.  Correlation between Ultrasonographic Appearance of Papillary Thyroid Microcarcinoma and BRAF V600E Mutation.

Authors:  Songnian Liang; Kun Huang
Journal:  J Oncol       Date:  2022-03-21       Impact factor: 4.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.